Mannkind (MNKD) Capital Expenditures Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 46.88% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.97% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 16.27% |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | -52.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.16% |
| Dec 31, 2025 | -26.69% |
| Sep 30, 2025 | 7.62% |
| Jun 30, 2025 | 33.78% |
| Mar 31, 2025 | -59.74% |
| Dec 31, 2024 | 53.79% |
| Sep 30, 2024 | -40.35% |
| Jun 30, 2024 | 161.77% |
| Mar 31, 2024 | 19.54% |
| Dec 31, 2023 | -53.37% |
| Sep 30, 2023 | -1,683.65% |
| Jun 30, 2023 | 339.44% |
| Mar 31, 2023 | 323.93% |
| Dec 31, 2022 | 37.62% |
| Sep 30, 2022 | -10.36% |
| Jun 30, 2022 | -95.22% |
| Mar 31, 2022 | 165.88% |
| Mar 31, 2019 | -38.28% |
| Mar 31, 2016 | -7.79% |
| Dec 31, 2015 | 69.40% |
| Sep 30, 2015 | 114.98% |
| Jun 30, 2015 | 231.02% |
| Mar 31, 2015 | 135.21% |
| Dec 31, 2014 | 217.54% |
| Sep 30, 2014 | 151.66% |
| Jun 30, 2014 | 26.12% |
| Mar 31, 2014 | -10.92% |
| Dec 31, 2013 | 16.15% |
| Sep 30, 2013 | -47.12% |